PLUR vs. CASI, SGMO, OMGA, BLUE, ATHA, DBVT, ALVR, DTIL, IKNA, and ELUT
Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include CASI Pharmaceuticals (CASI), Sangamo Therapeutics (SGMO), Omega Therapeutics (OMGA), bluebird bio (BLUE), Athira Pharma (ATHA), DBV Technologies (DBVT), AlloVir (ALVR), Precision BioSciences (DTIL), Ikena Oncology (IKNA), and Elutia (ELUT). These companies are all part of the "medical" sector.
Pluri (NASDAQ:PLUR) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
CASI Pharmaceuticals has higher revenue and earnings than Pluri. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.
16.6% of Pluri shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 10.2% of Pluri shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
CASI Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 72.91%. Given CASI Pharmaceuticals' higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Pluri.
CASI Pharmaceuticals received 200 more outperform votes than Pluri when rated by MarketBeat users.
CASI Pharmaceuticals has a net margin of -105.76% compared to Pluri's net margin of -6,339.59%. CASI Pharmaceuticals' return on equity of -110.11% beat Pluri's return on equity.
Pluri has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Summary
CASI Pharmaceuticals beats Pluri on 11 of the 14 factors compared between the two stocks.
Get Pluri News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
